Zoeken
Zoeken kan via de modus 'eenvoudig zoeken' (één veld) of uitgebreid via 'geavanceerd zoeken' (meerdere velden). Zo kan je bv. zoeken op een combinatie van een auteursnaam (auteur), een jaartal (jaar) en een documenttype.
Boekenmand
Nuttige resultaten kan je aanvinken en toevoegen aan een mandje. De inhoud hiervan kan je exporteren of afdrukken (naar bv. PDF).
RSS
Op de hoogte blijven van nieuw toegevoegde publicaties binnen uw interessegebied? Dit kan door een RSS-feed (?) te maken van jouw zoekopdracht.
nieuwe zoekopdracht
Molecular approaches to discover marine natural product anticancer leads – an update from a Drug Discovery Group collaboration
Crews, P.; Gerwick, W.; Schmitz, F.; France, D.; Bair, K.; Wright, A.; Hallock, Y. (2003). Molecular approaches to discover marine natural product anticancer leads – an update from a Drug Discovery Group collaboration. Pharm. Biol. 41(Supp.1): 39-52. https://dx.doi.org/10.1080/1388020039051743
In: Pharmaceutical Biology. Informa Healthcare: New York. ISSN 1388-0209; e-ISSN 1744-5116
|  |
| Auteurs | | Top |
- Crews, P.
- Gerwick, W.
- Schmitz, F.
- France, D.
|
- Bair, K.
- Wright, A.
- Hallock, Y.
|
|
| Abstract |
This paper outlines the results of a collaborative program begun in 1990 under the NIH National Cooperative Drug Discovery Group (NCDDG) program. It involves the unified research of a multi-institutional group from both academic and corporate laboratories. Our working hypothesis is that targets identified through basic molecular and cell biology studies are relevant for the treatment of human cancers. Thus, a broad range of primary biochemical assays have guided the examination of extracts obtained from marine organisms (both collected and cultured) and purified marine natural products. The goal is to discover small molecules effective against these biological targets. An ever-changing panel of assays focus on a number of cancer relevant targets associated with the cell cycle, signal transduction, angiogenesis or apoptosis. A massive library of materials has been assembled for evaluation in the screens and it consists of more than 900 compounds and 16,000 extracts. We believe that these samples have enormous potential for chemodiveristy and progress to date supports this contention. The first part of the paper focuses on highlights from the period 1995–1999. The two most important developments were that the bengamide and the psammaplin families provided important insights leading to the development of two compounds, LAF-389 and NVP-LAQ824. These were both advanced to Phase I anti-cancer clinical trials. A sampling of recent discoveries, including current leads in development is also discussed. Attention then turns to new technologies and strategies aimed at shortening the time interval from an initial lead candidate discovery to assessment of its future therapeutic potential. |
IMIS is ontwikkeld en wordt gehost door het VLIZ.
